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General: 
All products commercially available (including Aspartame 1, β-
Aspartame 2 and IPy2BF4) were purchased from Aldrich and used without 
further purification. Peptides 4, 5, and 6 were synthesized on solid 
support using standard Fmoc chemistry. Methylene chloride was 
distilled from calcium hydride and sodium metal. Liquid flash 
chromatography was carried out with Merck silica gel 60 (230-400 
mesh) and analytical thin layer chromatography (TLC) was performed on 
0.25 mm silica gel coated Kieselgel 60 F264 plates. The spots were 
visualized with UV light, and staining with nynhidrine followed by 
heat. NMR spectra were recorded on either a Bruker AMX-400 or AMX-300 
spectrometer. Chemical shifts are reported in parts per million (ppm) 
on the scale, using residual solvent peaks as reference. Reactions 
were carried out under nitrogen atmosfere. 
Analytical RP-HPLC was conducted using a C18 column (LiChrosorb, 
250×4 mm). Solvents: A= 0.1% TFA in H2O, B= 0.1% TFA in CH3CN. 
Detection: λ= 214 nm 
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Compound gradient tR 
1a 80-20%A (25 min) 11.44 
1b 80-20%A (25 min) 12.64 
2a 80-20%A (25 min) 10.83 
2b 80-20%A (25 min) 11.99 
3a 80-20%A (25 min) 15.04 
4a 80-20%A (25 min) 17.45 
4b 80-20%A (25 min) 18.39 
5a 80-20%A (25 min) 13.65 
5b 80-20%A (25 min) 14.81 
6a 70-20%A (20 min) 13.40 
6b 0-20%A (20 min) 14.25 
 
Semipreparative RP-HPLC was conducted using a 100 RP-8 column 
(LiChrospher, 250×10 mm, 10 µm). Solvents: A= 0.1% TFA in H2O, B= 
0.1% TFA in CH3CN. Detection: λ= 214 nm. 
MALDI-TOF-MS was conducted on a Voyager-DE STR Spectrometer, using α-
cianohydroxycinnamic acid as matrix. 
 
Synthesis of I-Aspartame derivatives: 
Method A: 100 mg (0.34 mmol) of the peptide were dissolved on a 
mixture of 10 ml of CH2Cl2 and 1 ml of TFA. 0.51 mmol of IPy2BF4 were 
added (solution turns dark pink). Reaction was stirred for 0.5 hours 
at room temperature. Solvent was removed in vacuo. The piridinium 
salt formed in the reaction was eliminated by filtration through a 
short column of silica gel using MeOH: TFA (10:1) as eluent: Rf of 
peptides= 0.85 (stained with nynhidrine and visible with UV light). 
Rf of pyridinium salt= 0.43 (visible with UV light). The resulting 
solid was washed with ether and further purified by reversed phase 
HPLC. 
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Method B: 100 mg of peptide (0.34 mmol) were dissolved on a mixture 
of 100 ml of CH2Cl2 and 10 ml of TFA. 0.75 mmol of HBF4 were added 
followed by addition of 0.37 mmol of IPy2BF4 (solution turns dark 
pink). The mixture was stirred at room temperature for o.5 hours. 
Work up of the reaction was the same as above. 
L-Asp-L-(2-I)-Phe-OMe 1a: 
1H-RMN (300 MHz, CD3OD): δ= 2.82-3.18 (m, 3H), 3.30-3.40 (m, 1H), 3.71 
(s, 3H), 4.13 (m, 1H), 4.79-4.84 (dd, 3J(H,H)= 5.9 Hz, 3J(H,H)= 9.6 
Hz, 1H), 6.97 (dt, 4J(H,H)= 1.7 Hz, 3J(H,H)= 7.9 Hz, 1H), 7.24-7.35 
(m, 2H), 7.85 (dt, 4J(H,H)= 1.1 Hz, 3J(H,H)= 7.9 Hz, 1H).  
13C-RMN (300 MHz, CD3OD): δ= 35.8 (CH2), 42.6 (CH2), 50.8 (CH), 53.0 
(OCH3), 54.1 (CH), 101.9 (C-I), 129.6 (CH), 130.0 (CH), 131.9 (CH), 
140.5 (C), 141.0 (CH), 169.4 (CO), 172.7 (CO), 173.0 (CO).  
L-Asp-L-(4-I)-Phe-OMe 1b: 
1H-RMN (300 MHz, CD3OD): δ= 2.78-3.24 (m, 4H), 3.79 (s, 3H), 4.16 (dd, 
3J(H,H)= 3.3 Hz, 2J(H,H)= 8.8 Hz, 1H), 4.73 (dd, 3J(H,H)= 5.3 Hz, 
2J(H,H)= 8.8 Hz, 1H), 7.04 (d, 3J(H,H)= 7.3 Hz, 2H), 7.66 (d, 3J(H,H)= 
7.3 Hz, 2H).  
13C-RMN (300 MHz, CD3OD): 36.3 (CH2), 37.7 (CH2), 51.1(CH), 53.3 (CH2), 
55.6 (OCH3), 93.3 (C-I), 132.6 (2 CH), 138.1 (C), 139.1 (2 CH), 169.7 
(CO), 173.0 (2CO).  
L-β-Asp-L-(2-I)-Phe-OMe 2a:  
1H-RMN (400 MHz, CD3OD): δ= 2.80 (dd, 3J(H,H)= 9.3 Hz, 2J(H,H)= 8.0 
Hz, 1H), 2.99 (dd, 2J(H,H)= 8.0 Hz, 3J(H,H)= 3.6 Hz, 1H), 3.11 (dd, 
3J(H,H)= 13.9 Hz, 2J(H,H)= 9.5 Hz, 1H), 3.35 (dd, 3J(H,H)= 6.1 Hz, 
3J(H,H)= 5.9 Hz, 1H), 3.70 (s, 3H), 4.13 (dd, 3J(H,H)= 9.3 Hz, 
3J(H,H)= 3.6 Hz, 1H), 4.82 (dd, 2J(H,H)= 9.5 Hz, 3J(H,H)= 5.9 Hz, 1H), 
6.97 (t, 3J(H,H)= 7.7 Hz, 1H), 7.24 (d, 3J(H,H)= 7.5 Hz, 1H), 7.32 
(t, 3J(H,H)= 7.5 Hz, 1H), 7.86 (d, 3J(H,H)= 7.7 Hz, 1H).  
13C-RMN (400 MHz, CD3OD): δ= 36.1 (CH2), 42.7 (CH2), 50.9 (CH), 53.0 
(OCH3), 54.0 (CH), 101.0 (C-I), 129.6 (CH), 130.1 (CH), 131.9 (CH), 
140.6 (C), 141.0 (CH), 169.4 (CO), 172.6 (CO), 172.9 (CO). 
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L-β-Asp-L-(4-I)-Phe-OMe 2b: 
1H-RMN (400 MHz, CD3OD): δ= 2.69 (dd, 3J(H,H)= 9.2 Hz, 2J(H,H)= 7.9 
Hz, 1H), 2.92 (m, 2H), 3.21 (dd, 3J(H,H)= 4.0 Hz, 3J(H,H)= 5.0 Hz, 
1H), 3.72 (s, 3H), 4.08 (dd, 2J(H,H)= 9.5 Hz, 3J(H,H)= 4.0 Hz, 1H), 
4.71 (dd, 2J(H,H)= 9.5 Hz, 3J(H,H) = 5.0 Hz, 1H), 7.03 (d, 3J(H,H)= 
8.4 Hz, 2H), 7.65 (d, 3J(H,H)= 8.4 Hz, 2H).  
13C-RMN (400 MHz, CD3OD): 36.8 (CH2), 37.5 (CH2), 51.3(CH), 53.0 
(OCH3), 55.2 (CH), 93.0 (C-I), 132.3 (2 CH), 137.9 (C), 138.9 (2 CH), 
169.7 (CO), 172.7 (CO),174.0 (CO). 
Ac-L-β-Asp(OMe)-L-(2-I)-Phe-OMe 3a: 
1H-RMN (300 MHz, CDCl3): δ= 2.01 (s, 3H), 2.70-2.77 (dd, 3J(H,H)= 4.6 
Hz, 2J(H,H)= 15.9 Hz, 1H), 2.88-2.95 (dd, 3J(H,H)= 4.6 Hz, 2J(H,H)= 
15.9 Hz, 1H), 3.08-3.15 (dd, 3J(H,H)= 8.3 Hz, 2J(H,H)= 14.0 Hz, 1H), 
3.26-3.332 (dd, 3J(H,H)= 8.3 Hz, 2J(H,H)= 14.0 Hz, 1H), 3.68 (s, 3H), 
3.72 (s, 3H), 4.75-4.89(m, 2H), 6.31 (d, 3J(H,H)= 7.9 Hz, 1H), 6.71 
(d, 3J(H,H)= 7.7 Hz, 1H), 6.93 (t, 3J(H,H)= 6.0 Hz, 1H), 7.17 (d, 
3J(H,H)= 6.0 Hz, 1H), 7.28-7.31 (m, 1H), 7.82 (d, 3J(H,H)= 6.8 Hz, 
1H).  
13C-RMN (300 MHz, CDCl3): δ= 23.5 (CH3), 37.7 (CH2), 42.6 (CH2), 49.1 
(CH), 53.0 (2 OCH3), 53.1 (CH) 101.3 (C-I), 128.8 (CH), 129.2(CH), 
130.6 (CH), 139.4 (C), 140.1 (CH), 170.1 (CO), 170.5 (CO), 171.6 
(CO), 172.0 (CO).  
For-NLeu-Leu-(2-I)-Phe-OMe 5a:  
1H-RMN (400 MHz, CD3OD+D2O): δ= 0.95-1.02 (m, 10H), 1.39 (m, 4H), 
1.59-1.79 (m, 5H), 3.16 (dd, 3J(H,H)= 9.0 Hz, 3J(H,H)= 13.9 Hz, 1H), 
3.31 (m, 1H), 3.39 (m, 1H), 3.76 (s, 2H), 4.12 (dd, 2J(H,H)= 6.0 Hz, 
3J(H,H)= 7.5 Hz, 1H), 4.49 (dd, 2J(H,H)= 6.0 , 3J(H,H)= 9.3, 1H), 7.04 
(t, 3J(H,H)= 7.9 Hz, 1H), 7.21 (d, 3J(H,H)= 7.5 Hz, 1H), 7.39 (t, 
3J(H,H)= 7.5 Hz, 1H), 7.90 (d, 3J(H,H)= 7.9 Hz ,1H), 8.17 (s, 1H). 
13C-RMN (400 MHz, CD3OD+D2O): δ= 14.8 (CH3), 22.6 (CH3), 23.7 (CH3+CH2), 
26.1 (CH3), 29.2 (CH2), 33.3 (CH2), 42.3 (CH2), 43.4 (CH2), 53.4 (CH), 
53.6 (OCH3), 53.9 (CH), 54.2 (CH), 101.6 (C-I), 130.1 (CH), 130.4 
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(CH), 132.4 (CH), 141.0 (C), 141.2 (CH), 164.5 (CHO), 173.8 (CO), 
174.2 (CO), 174.9 (CO). 
H2N-Gly-Gly-(2-I)-Phe-Leu-OMe 4a: 
1H-RMN (300 MHz, D2O): δ= 0.92 (d, 3J(H,H)= 5.9 Hz, 3H), 0.96 (d, 
3J(H,H)= 6.2 Hz, 3H), 1.65 (m, 3H), 3.20 (dd, 3J(H,H)= 7.4 Hz, 
2J(H,H)= 13.6 Hz, 1H), 3.34 (dd, 3J(H,H)= 7.9 Hz , 2J(H,H)= 13.6 Hz , 
1H), 3.75 (s, 3H), 3.94 (s, 2H), 4.04 (s, 2H), 4.50 (t, 3J(H,H)= 8.5 
Hz, 1H), 4.95 (m, 1H), 7.09 (t, 3J(H,H)= 7.7 Hz, 1H), 7.32 (d, 
3J(H,H)= 7.7 Hz, 1H), 7.44 (t, 3J(H,H)= 7.5 Hz, 1H), 7.99 (d, 3J(H,H)= 
7.9 Hz, 1H). 
13C-RMN (300 MHz, D2O): δ= 20.8 (CH3), 22.1 (CH3), 24.3 (CH), 39.6 
(CH2), 40.5 (CH2), 41.8 (CH2), 42.1 (CH2), 51.5 (OCH3), 53.0 (CH), 
53.8 (CH3), 100.3 (C-I), 128.7 (CH), 129.2 (CH), 130.8 (CH), 138.8 
(C), 139.8 (CH), 167.7 (CO), 170.6 (CO), 172.3 (CO), 174.4 (CO). 
Ac-Ala-Asp-Ala-Thr-(2-I)-Phe-NH2 6a: 
1H-RMN (400 MHz, CD3CN): δ= 0.84 (d, 3J(H,H)= 6.1 Hz, 3H), 1.74 (d, 
3J(H,H)= 7.0 Hz, 8H), 2.46 (m, 3H), 3.49 (dd, 3J(H,H)= 9.8 Hz, 
3J(H,H)= 14.0 Hz, 3H), 3.70-3.75 (dd, 3J(H,H)= 5.5 Hz, 3J(H,H)= 14.0 
Hz, 1H), 4.39-4.45 (m, 1H), 4.54 (d, 3J(H,H)= 6.7 Hz, 1H), 4.99 (t, 
3J(H,H)= 6.7 Hz, 1H), 5.09 (m, 1H), 7.40 (t, 3J(H,H)= 6.4 Hz, 1H), 
7.68-7.77 (m, 2H), 8.28 (d, 3J(H,H)= 7.7 Hz, 1H). 
Pd coupling of L-Asp-L-(2-I)-Phe-OMe 1a with phenylboronic acid: 
100 mg of L-Asp-L-(2-I)-Phe-OMe 1a (0.24 mmol) were dissolved in 3ml 
of toluene and 2 ml of MeOH. 58 mg of PhB(OH)2 (0.48 mmol) and 10 mg 
of Pd(PPh3)4 (5% mmol) were added. Reaction was stirred at 80°C for 5 
hours. After cooling at room temperature, mixture was filter through 
celite and solvents were removed in vacuo. Residue was purified by 
semipreparative reversed phase HPLC (C-18 column (250×16 mm), flow= 
4ml/min, gradient 80-20%A in 30 min, tR= 14.33 min)  
L-Asp-L-(2-Phenyl)-Phe-OMe 7: 
 6
1H-RMN (300 MHz, CD3OD): δ= 2.78-2.88 (m, 1H), 2.89-3.09 (m, 2H), 3.40 
(s, 3H), 4.38 (m, 1H), 4.64 (m, 1H), 4.99-5.13 (m, 1H), 7.10-7.33 (m, 
7H), 7.97-8.09 (m, 2H). 
13C RMN (300 MHz, CD3OD): (Some signals are double due to the presence 
of rotamers). δ= 31.5 (CH2), 32.6 (CH2), 34.6 (CH2), 38.2 (CH2), 53.7 
(CH), 55.8 (CH), 60.7 (OCH3), 61.3 (OCH3), 116.7 (CH), 117.2 (CH), 
126.0 (CH), 126.1 (CH), 126.4 (CH), 131.3 (C), 131.4 (C), 141.1 (C), 
142.2 (C), 142.6 (C), 166.1 (CO), 166.4 (CO), 170.5 (CO), 171.4 (CO), 
171.6 (CO), 173.6 (CO). 
HPLC-ES: 370 (M+1). 
 
